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VI. Birth Defects and Genetic Disorders 
L PRENATAL DIAGNOSIS 
The diagnosis of heritable disease during early fetal life has 
made exciting progress in the past decade. During this period. 
prenatal diagnosis has become a major adjunct to genetic 
counseling and is being used by thousands of couples to provide 
information by which they decide to either continue or termi-
nate a pregnancy. The diagnostic information and pregnancy 
options allow them a reasonable likelihood of having normal 
children. The challenge for the next decade is to expand knowl-
edge of human fetal development, to widen fetal diagnostic 
capabili ties in early pregnancy, and to find ways to initiate 
treatment during fetal life. Glimpses of Success in these pursuits 
have already appeared. 
The most important technique for prenatal diagnosis has 
been amniocentesis to obtain amniotic fluid and the cells 
therein. These amniotic cells are fetal in origin and express 
considerable genetic information about the unborn child. Met-
abolic products from the fetus can be measured in the fluid, 
and chromosome examination and enzyme assays can be carried 
out with cultured amniotic cells. Homocystinuria, Fabry's dis-
ease, and the several mucopolysaccharidoses are examples of 
inborn errors of metabolism with skin manifestations that have 
been diagnosed prenatally. 
Two othel: techniques have been applied to prenatal diagnosis 
with considerable success. One of these is the noninvasive 
examination of the pregnant uterus by ultrasonography to 
delineate both surface and internal organ anatomy of the fetus. 
The second is the entry into the uterus by fetoscopy to directly 
view and biopsy the fetus. Blood samples have been obtained 
from vessels on the chorionic plate of the placenta. The avail-
ability of blood has made possible the diagnosis of beta-thal-
assemia, sickle cell anemia, and Duchenne muscular dystrophy, 
all disorders that could not be diagnosed by amniocentesis. The 
potential uses of blood to make diagnoses, to study the meta-
bolic state of the fetus, and to monitor drug administration and 
other therapies in the fetus are enormous. 
The direct view of the fetus has made possible the diagnosis 
of certain dysmorphic syndromes for which ultrasound infor-
mation was not sufficiently precise. During fetoscopy a detailed 
view of the scalp and its hairs, the skin, dermal ridges, hair 
follicles, and finger- and toenails can be obtained. Skin can be 
biopsied from the scalp and from the trunk of the fetus. The 
tiny, I-mm skin fragments can be used for cell culture, light 
and electron microscopic examination, and biochemical mea-
surements. One pregnancy at risk for the recessively inherited 
harlequin fetus type of congenital ichthyosis has been examined 
by fetoscopy and fetal skin biopsy. Visual examination of the 
skin and skin appendages in utero and electron microscopic 
examination of the biopsy showed them to be normal, and a 
normal infant was born 5 months later. 
Further development of prenatal diagnosis and prenatal ther-
apy will undoubtedly continue. We may find it possible to 
follow the nutritional status of the fetus with skin, hair, or blood 
biopsy. Drug levels could also be measured in these tissues. 
Fetal skin or blood may become a place to detect environmental 
teratogens either to establish etiologic relationships or to mon-
itor chemical pollution of the intrauterine environment. 
Prevalence and Severity 
In a newborn population, around 3% has some type of birth 
defect that is considered to be of primary genetic origin. Birth 
defects that are detected after birth are only a small fraction of 
all genetic abnormalities at conception. Most are thought to 
result in spontaneous abortions. 
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Genetic disorders fall into 3 general classes: multifactorial 
(caused by environmental interaction with many different 
genes) monogenic or mendelian and chromosomal. The approx-
imate percent in the newborn population is indicated in Table 
1. Many of these disorders have primary skin manifestations, 
such as neurofibromatosis, tuberous sclerosis, achondroplasia, 
cystic fibrosis, albinism and several of the chromosomal dis-
eases. Most of these disorders cannot be diagnosed in utero 
because the genetic defects producing the disorders have not 
been adeq uately defined in cultured skin cells. This table does 
not include children affected by Rh incompatibility (erythro-
blastosis fetalis), since recent use of anti-Rh immune globulin 
has essentially removed this disease from the newborn popu-
lation. Neither does the table include high frequency disorders 
with relatively low burden or ethnic specificity, such as glucose-
6-phosphate dehydrogenase deficiency, which affects 5-10% of 
males; sickle cell disease, which affects approximately 0.25% of 
the black population; thalassemia, which affects approximately 
2% of the Mediterranean and Oriental populations; or Tay 
Sachs Disease-hexosaminidase A deficiency. which produces 
neurological deterioration in approximately 0.04% of the Ash-
kenazi Jewish population. The last disease has disappeared 
from the Jewish newborn population in the U.S. because of 
mass genetic screening of adult populations. 
Approximately 250,000 newborns a year in the U.S. will be 
affected by one of these severely disabling lifelong diseases. 
Cost estimates for these calamitous diseases cannot be made 
easily. One would have to take into account not only the cost of 
health care delivery and maintenance of the handicapped but 
also the loss to the community in talent, productivity, earnings, 
and taxes that such people would contribute if genetic disorders 
could be eradicated. 
Prevention, Treatment, and Cure 
Six biochemical inherited disorders can be diagnosed in the 
newborn by using a low cost technique effective in mass screen-
ing in which dried blood is applied to fliter paper. They are 
PKU, homocystinuria, maple syrup urine disease, t~osinemia, 
galactosemia, and hypothyroidism. MeI?t~ retardatlO~, follow-
ing these conditions, can be prevented if infants are dIagnosed 
and treated within the first 3 weeks of life. These diseases will 
not be discussed. . 
For other diseases mass screening diagnostic techniques and 
effective therapy are not available. Some of these other diseases 
can be diagnosed with amniocentesis or fetal visualization tech-
niques during the fIrst 20 weeks of gestation. Others, including 
those of enzyme defects not measurable in the amniotic fluid, 
cannot be diagnosed in utero. For all genetic disorders without 
effective therapy the only prevention is genetic counseling; the 
only cure is elective therapeutic abortion. It is this group of 
disorders that will be emphasized in the discussion. 
Methods for prenatal diagnosis. Amniocentesis is the most 
useful of the diagnostic methods. The technique was originated 
by Fuchs in 1956. Better methods for the culture of hum~n cells 
in vitro were developed at about the same tune, and ill 1966 
Steele and Breg worked out methods for examination of fetal 
chromosomes. Amniocentesis will be discussed in detail. 
The fetus may also be looked at directly with an instrument 
termed a fetoscope. For this purpose, the fetoscope is inserted 
into the amniotic cavity through a 2-mm cannula. Because of 
the relatively large diameter of the instrument, fetoscopy runs 
the risk of causing premature uterine contractions and placental 
or uterine bleeding. It has been used successfully to sample 
fetal blood from placental vessels for the diagnosis of Duch-
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TABLE I. Estimated frequency (%) of the different genetic disorders in the newborn population (total 2.56%) 
Chromosomal disorders-0.55" 
Autosomal 
Trisomy 21 
Trisomy 18 
Trisomy 13 
Other 
0.13 
0.03 
0.02 
0.02 
0.20 
Sex Chromosome 
XO and X deletions 
Other "severe" defects 
XXY 
XXX 
XYY 
Others 
o 
0.01 
0.1 
0.1 
0.1 
0.015 
0.35 
Monogenic (Mendelian) disorders-0.36 
Autosomal recessive X-Linked Autosomal dominant 
Mental retardation, severe 
Cystic fibrosis 
0.08 
0.05 
0.02 
0.01 
0.01 
0.01 
0.01 
0.005 
0.001 
0.0005 
0.25 
Duchenne muscular dystrophy'" 
Hemophilias A and B'" 
0.02 
0.01 
0.02 
Blindness 
Deafness 
0.01 
0.01 
0.005 
0.005 
0.005 
0.005 
0.005 
0.015 
0.06 
Deafness, severe 
Adrenogenitai syndrome" 
Albinism 
Phenylketonuria 
Other amino acid urias" 
Muccopolysaccharidoses" 
Tay-Sachs disease" 
Galactosemia" 
Othersb• ,. Marfan syndrome 
Achondroplasia 
Neurofibromatosis 
Myotonic dystrophy 
T uberous sclerosis 
Others 
Multifactorial disorders-1.65 
Congenital malformations 
Spina bifida and anencephaly" 
Congenital heart defects 
Pyloric stenosis 
Club feet 
Cleft lip and palate 
Dislocated hips 
" Diagnosable in utero. 
b Some diagnosable in utero. 
C Fetal sex can be determined. 
0.45 
0.4 
0.3 
0.3 
0.1 
0.1 
1.65 
ennes muscular dystrophy and for some of the abnormalities of 
herrlOglobin metabolism, such as thalassemia ' and sickle cell 
disease. Through the combined use of sonography and fetos-
copy, fetal blood has been obtained from the placenta for 
investigation of hemoglobin structure and synthesis. Since the 
fetus after the fIrst few months of gestation makes primarily 
fetal hemoglobin that is composed of alpha and delta chains, it 
is possible to detect all the alpha chain abnormalities during 
early embryogenesis. It is more difficult to diagnose beta chain 
abnormalities, such as sickle cell disease, since the fetus makes 
only a small amount of beta chains at this stage of gestation. 
Sickle cell disease and beta-thalassemia have been diagnosed 
by radioisotopic methods. Fetal blood has been obtained and 
assayed directly for elevated creatinine phosphokinase as an 
indicator of Duchennes muscular dystrophy. For an X-linked 
recessive trait male fetuses would be at risk with 50% probability 
of having an X-linked recessive trait. If a fetus were ascertained 
to be a male by traditional karyotyping of cultured amniotic 
fluid cells, a more precise diagnosis could then be made by 
fetoscopy and creatinine phosphokinase determination of se-
rum. 
Another indirect approach is through radiological visualiza-
tion of the fetus. A signifIcant abnormality in the size of a fetal 
part, such as absence of the head, is necessary for effective 
diagnosis. In some instances, radioopaque contrast media are 
placed in the amniotic sac to augment this technique. The 
technique has not been extensively used. 
Perhaps the most useful direct visualization has evolved from 
ultrasonic scanning. Sonography is used to diagnose twin preg-
"Common" diseases 
(e.g. diabetes, malignancy, allergies) ?? 
nancies, to localize the placenta during insertion of the needle 
for amniocentesis, and to determine the fetal age by the bipar-
iatal diameter. The technique also makes possible the prenatal 
diagnosis of anencephaly or other missing major parts. Some 
improvements in ultrasound methods are being made such as 
gray-scale scanning to improve gradations of tissue density and 
real-time scanning that, through continuous monitoring, pro-
vide better defInition of external and internal fetal structures. 
Amniocentesis. In basic amniocentesis 20 rn1 of amniotic fluid 
are obtained by inserting a needle through the suprapubic area 
into the amniotic cavity under sonograph visualization. The 
cellular components of the amniotic fluid are centrifuged and 
the diverse cells that are of fetal origin are placed in culture 
and used for biochemical or chromosomal analysis. In some 
situations uncultured cells are used for direct cytological or 
biochemical analysis. Uncultured cells for ultrastructural ex-
amination have been especially useful in the diagnosis of lyso-
somal storage disease in which undegraded molecules are stored 
within the genetically defective lysosomes. Usually this requires 
the use of an electron microscope. Uncultured cells have been 
used to determine sex, either X (Barr bodies) or Y bodies 
(fluorescent on quinaqurine staining). The soluble components 
of the amniotic fluid have also been used for analysis. In most 
instances, however, it has not been useful during the early 
second trimester since maternal circulation removes accumu-
lated precursors and blocks metabolic sequences. Thus, PKU, 
MSUD, etc., do not have elevated amniotic fluid levels of 
phenylalanine or branched chain amino acids: In certain in-
stances, however, enzymes are freed into the amniotic fluid. 
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Usually these are lysosomal enzymes. When this is the case, 
pregnancies at risk are deficient in Hunter's syndrome enzymes 
(alpha-L-iduronicacid-2-sulfatase) and Tay-Sachs (hexosamin-
idase A) enzymes. Where alpha protein is secreted in excess 
from the serum into the amniotic fluid, open neural tube 
anomalies are present, and so are certain other disorders, such 
as nephrosis. 
Most prenatal monitoring is based on the analysis of cultured 
cells. At least 3 types of cells have been grown from amniotic 
fluid : an epitheloid-like cell, a fibroblastic cell, and an amniotic 
fluid cell. Amniotic fluid cells are the dominant cell type in 
most early cultures. In prolonged cultures fibroblast-like cells 
overgrow the culture media with multiple population doublings. 
The epithelioid-like cells grow very slowly and are difficult to 
maintain in culture. The media and general techniques for 
culturing cells from amniotic fluid are quite similar to those 
techniques for culturing skin fibroblasts. The most important 
aspect for culturing cells is the skill and individual handling of 
cell culture. 
Status of Research 
Only a very few heritable dermatologic disorders have either 
clear-cut mendelian phenotypes or specific pathognomonic 
characteristics that would make them identifiable by currently 
available prenatal monitoring techniques. However, in the fu-
ture severely incapacitating disorders may be understood and 
then become subject to prenatal monitoring through the expres-
sion of cultured skin fibroblasts. 
It may be possible to get more information from cultured 
fibroblasts; a novel approach has been suggested by Kan et al. 
Even though ·a certain gene is not expressed in cultured fibro-
blasts (such as the alpha chain of hemoglobin), this gene still 
exists as a specific DNA sequence in the cultured amniotic fluid 
cell. In fact, prenatal diagnosis of alpha-thalassemia has been 
made by noting the absence of the specific DNA in the fetus at 
risk. It is likely that other disorders with gene deletions, such 
as alpha-thalassemia, may be diagnosed if the specific messen-
ger RNA or DNA can be isolated. 
In looking toward the future it must be recognized that the 
prevention of birth defects through prenatal monitoring and 
termination of pregnancy carries with it serious ethical consid-
erations that could very well prevent widespread use. Even if 
application of prenatal diagnosis becomes available in fam~ies 
who have had an abnormal child already, only a small reductIOn 
in disease incidence will take place because only a small portion 
of all birth defects are caused by a single gene. Ninety percent 
of such common problems as neural tube anomalies are fust 
time occurrences in a family. Thus, other approaches, such as 
mass screening for either heterozygote detection or abnormal 
fetuses, must be developed. Programs to determine matern~ 
serum alpha-fetoprotein levels for subsequent prenatal mOnI-
toring are likely prospects for the near future. Mass screening 
for heterozygotes is already a reality. Prevention of Tay-Sachs 
disease is an example of what mass screening for hexosamini-
dase A deficiency can do. Parents who are both found to be 
carriers of Tay-Sachs disease may avail themselves of prenatal 
monitoring. In Atlanta mass screening of the Ashkenazi Jewish 
population has resulted in no births of Jewish children with 
Tay-Sachs disease in the last 3 years; however, outside of the 
program several patients of non-Jewish origin have been born 
with the disease. 
Prenatal diagnosis has been made by ascertaining closely 
linked genes to mutations. Thus, if secretor of HLA or other 
antigenically defmable defects are linked, they may be used as 
a marker to determine the presence or absence of a mutant 
gene in the amniotic fluid cell. The differentiation problem may 
be attacked by fusing amniotic fluid cells with cell lines capable 
of "activating" their total genetic constitution. For example 
albumin is normally synthesized only in liver cells, but mouse 
fibroblasts will produce albumin if fused with rat hepatoma 
cells. To de-differentiate human fibroblasts is still in the realm 
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of research. In several disorders, disease occurs in utero (cysti-
nosis lipid hexosaminidase-A deficiency, etc.); at some distant 
time prenatal diagnosis may be coupled with genetic engineer-
ing for direct treatment of affected fetuses while still in utero. 
Although most of all this is in the realm of science fiction, the 
public has been made to believe that successful introduction of 
genes or enzymes in enzyme deficient cells may be d~ne, if not 
now, soon. It is unlikely, however, that the fetus will be the 
subject of such experimental efforts in the near future. 
Needs for Additional Basic Research 
Little is known about the pathogenesis of genetic disorders. 
Collaborative interdisciplinary research is needed to improve 
our understanding of the basic mechanisms that produce all 
genetic disorders; communication ~~ong biocheITo'-i~ts, cell bi-
ologists, molecular biologists, genetIcIsts, and phYSICIans of var-
ied traditional backgrounds must be encouraged. 
There is a pressing need for continuing research of the 
molecular mechanisms that produce observed phenotypes. Al-
though specific enzymes associated with human phenotypic 
expression have been recognized as impaired, ~he number of 
variables is so great that diverse forms of expressIOn may occur. 
For instance there are at least 3 different patterns of monogenic 
inheritance that produce albinism, and these differences are not 
reflected as altered pathways for melanin synthesis. Very few 
heritable disorders of the skin have clearly defined biochemical 
bases. Effort should be made toward understanding the basic 
mechanisms of these diseases. 
The field of prenatal monitoring must overcome at least 3 
basic methodological limitations in the use of cultured amniotic 
fluid cells. The fust limitation is our necessary reliance on 
fibroblast cultures. Only those enzymes that are present in 
cultured skin fibroblasts or fibrob last-like cells can be studied. 
Therefore, those conditions that are limited to differentiated 
organs, such as the liver (glycog~n storage disease, Typ.e I, or 
phenylalanine hydroxylase defiCIency) cannot be studIed by 
current culture techniques. The same limitations apply to en-
zyme deficiencies that affect only the skin. 
The second limitation is that amniotic fluid-like cells express 
themselves biochemically in a different way from cultured skin 
fibroblasts. Thus, if cultured cells are used to diagnose collagen 
diseases on the basis of specific abnormal collagen, the type of 
cell culture must coincide with the type of cell producing the 
abnormal collagen. This is not always possible with amniotic 
fluid cells; amniotic fluid cells produce collagen with a strong 
resemblance to basement membrane collagen whereas fibro-
blast-like cells make collagen indistinguishable from that of 
dermal fibroblasts. 
The third limitation is that in order to obtain enough cells 
for one enzyme assay between 4 and 8 weeks of culture are 
required. This is far too long to make rou~ine assays practicable 
as diagnostic tools. Further research IS needed to develop 
prenatal diagnostic systems and microassay tec~niques; .spe~if­
ically, ultramicrospectrophotometry, wa!'s to .dlfect antIbodIes 
at cell surface antigens or specific protems, smgle-cell electro-
phoresis, and single-cell enzymes assays. 
Many research laboratories are producing enzyme assays for 
specific research projects; the fruits of ~hese researches are n~t 
passed on for use in health care servIces. Conversely, public 
health needs and epidemiological observations are not passed 
on to basic science investigations. There is a clear need for 
collaboration among public health departments, basic science 
investigators, university health centers, and private doctors. 
Some institution, such as the Center for Disease Control, should 
act as an intermediary. 
Needs for Additional Clinical Research 
There is a need for additional development of ways to follow 
the nutritional status and drug levels of the fetus with fetal 
biopsies of skin, hair, or blood. Fetal skin or blood could also be 
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used as sampling sites for environmental teratogens, in order to 
establish etiological relationships, and to establish how much 
chemical pollution of the intrauterine environment has oc-
curred. A fIrst step is to develop better fIber optics and biopsy 
tools. Some heritable cutaneous disorders, such as albinism, 
ectodermal dysplasia, neurofIbromatosis, etc., might be diag-
nosed prenatally if differentiated cells from specifIc cellular 
components could be biopsied and maintained in culture in a 
differentiated state. Similarly, disorders involving primary liver 
enzymes, such as acute intermittent porphyria or some of the 
glycogen storage diseases, might be amenable to diagnosis by 
direct visualization, liver biopsy, and maintenance of the liver 
cells in a differentiated state in cultw·e. There are good pros-
pects for better visualization as smaller and better fiber optics 
are developed and better positional control of biopsy tools is 
achieved. 
Interdisciplinary study of the ethics of preventative programs 
is needed, and studies on future legal and political consequences 
of prenatal diagnosis and therapy deserve serious consideration. 
2. DEVELOPMENTAL DEFECTS 
Prevalence and Severity 
Approximately 3-5% of all infants are born with congenital 
malformations. Two percent of all infants are born with a major 
malformation, which is defIned as an anomaly that is disfIguring 
or has surgical consequences, such as repair of a club foot 
deformity or cleft lip and palate. Congenital malformations are 
the most common cause for admission of children to hospitals 
in North America. Very often, surgical correction of a major 
anomaly requires that the child be hospitalized many times 
during his formative years. Frequently the disfigurement and 
protracted correction procedures result in emotional trauma 
that may eventually require psychiatric attention. Loss of time 
from school further interferes with the normal maturation 
process of the child. The tutoring required and the eventual 
loss of productivity are but a small part of the eventual costs of 
these malformations. 
Approximately 7% of infants have a cutaneous lesion that is 
visible at birth. A small percentage of these infants are included 
in the group of congenital malformations mentioned above. 
Congenital cutaneous lesions are often disfIguring. This is es-
peciaUy true of the giant, pigmented mole that covers Ia:ge 
areas of the body and the port-wine stain that, in associatIOn 
with the Stw'ge-Weber syndrome, may cover a large area of the 
face . Both of these disorders may be complicated by other 
manifestations: malignant melanoma in the former and seizures 
and mental retardation in the latter. In addition to these 2 
lesions, approximately 0.4% of newborns have a nevus, a cafe-
au-lait mark, or a hemangioma involving the face, all very 
unsightly if large. 
Prevention, Treatment, and Cure 
At present, the only way to prevent congenital malformations 
is through genetic counseling, and this is not always successful. 
Only about 70% of congenital malformations have a known 
cause, and although t he majority of these malformations are 
genetic, the only method for initially determining the presence 
of an abnormal genets) in a family is through the birth of a 
child with a malformation. These are very vew genetic diseases 
that can be detected in normal, healthy people before the birth 
of an affected infant. 
Prenatal diagnosis by amniocentesis is most useful to detect 
chromosome disorders and inborn errors of metabolism. The 
majprity of isolated birth defects (including all 10 of the der-
matologic malformations) however, cannot be diagnosed pre-
natally. 
Genetic counseling is most benefIcial when (1) at least one 
member of a family is already affected, (2) the risk of recurrence 
is known from prior family studies, and (3) a means exists for 
making prenatal diagnosis via amniocentesis. 
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Some of the major congenital malformations are amenable 
to therapy and, occasionally, can be cured by surgical interven-
tion. However, the necessary multiple procedures often cause 
emotional trauma, loss of productivity, and economic hardship, 
particularly in the case of the giant pigmented nevus. 
The neural tube defects, myelomeningocele and anenephaly, 
serve as models for future research in prevention of genetic 
disease. This group manifests typical multifactional inheritance 
with recurrent risk dependent on the population studied. It was 
discovered in 1972 that at approximately the 15th week of 
gestation, the level of a1pha-fetoprotein (a fetal-specifIc protein) 
is markedly elevated in the amniotic fluid if the fetus has an 
open neural tube defect. In 1973, it was also determined that 
the level of a1phafetoprotein in maternal serum can be elevated 
at about the 15th week of gestation if the fetus has an open 
neural tube defect. If the entire population of primiparous 
women could have their serum screened for elevated FP during 
the 15th week of gestation, the risk of a fIrst born with this 
anomaly could be reduced . However, the methodology for this 
screening is far from perfect: both false negative and false 
positive results are obtained. 
Statu.s of Basic Research 
Seventy percent of congenital malformations have a known 
cause; most are genetic in origin. They are the result of chro-
mosome disorders, autosomal recessive or dominant disorders, 
X-linked disorders or multifactorial inheritance. A very small 
percentage are secondary to known teratogens. Therefore, fully 
30% of all congenital anomalies have no known cause. It is 
assumed that these are produced by some environmental influ-
ence or other teratogen. A great majority of the congenital 
cutaneous lesions fall within this group of unknown etiology. 
Most of our knowledge about the effects of teratogens comes 
from experiments in which various congenital malformations 
were produced by feeding pregnant laboratory animals various 
drugs or chemicals or by innoculating them with infectious 
agents. Despite the difficulty of relating the effect in a labora-
tory animal to that in a human being, several very worthwhile 
principles have emerged from the study of teratogenesis in 
animals. 
A teratogen need only act for a very short period of time to 
produce its effect. For example, rats were fed the teratogen, 6-
amino-nicotinamide, on the 11th day of pregnancy, followed 
two hours later by administration of the vitamin nicotinamide 
at a dose known to reverse the effects of the teratogen. Cleft 
palate still occurred in the offspring despite the very brief 
exposure to the teratogen: 
A teratogen can produce different types of anomalies or no 
anomalies at all depending on when the fetus is exposed. When 
rats are given thalidomide on all but the 12th day of gestation, 
"no anomalies occur." However, when the drug is given on the 
12th day of gestation, the typical limb malformations do occur. 
Careful timing of administration of the drug to white rabbits 
during the 8th to 16th day of pregnancy demonstrated the same 
temporal specificity. The action of rubella is similar. When the 
infection occurs during the first or second month of pregnancy, 
heart and eye defects predominate; in the third, hearing defects 
are most common; after the third month, no anomalies occur. 
These "sensitive" periods vary from one animal to another and 
even across species lines, thus making it diffIcult to correlate 
effects of a teratogen in a laboratory animal with effects in a 
human being. 
A good deal of investigation has taken place on the terato-
genic effects of specifIc vitamin defIciencies in laboratory ani-
mals. Each vitamin deficiency is associated with very specifIc 
malformations within each species of animal. These experi-
ments tend to dispel the popularly held belief that the fetus 
will take all the nutrients it needs from its mother. Obviously, 
this principle has far-reaching implications for clinical research 
in humans. 
It has also been noted that hormone defIciencies and excesses 
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can be teratogenic of themselves. Various hormones can also 
potentiate the effects of other teratogens. 
Several experimental models have shown that genetic factors 
may influence the results of exposure to a teratogen. When 3 
different strains of rats are exposed to the azo dye, trypan blue, 
exencephaly occurs in 17%, 50%, and 90% of the offspring 
respectively. In another experiment trypan blue was adminis-
tered to 200 pregnant rats. It was noticed that rat fetuses within 
the same uterus ranged from normal to severely malformed to 
dead. Genetic differences of the various rat fetuses most readily 
explain the variance. T he genetic influence on the action of 
teratogens in laboratory animals serves as an excellent proto-
type for multifunctional inheritance in humans. Other basic 
research has been concerned with isolated genetic disorders and 
is described elsewhere. 
These animal studies certainly demonstrate that teratogen 
research in humans will be a formidable task. 
Status of Clinical Research 
The major portion of clinical research pertaining to congen-
ital malformations has been involved with organ systems other 
than the skin since most of the cutaneous findings are not 
associated with severe disability. However, studies of other 
malformations have bearing on future investigations concerning 
cutaneous congenital malformations. As with the basic science 
research, a good deal of effort has been expended in trying to 
define the underlying causes of congenital malformations, and, 
in large population studies, the majority has been found to be 
genetic . Recently, more attention has been paid to environmen-
tal factors (teratogens) as etiologic agents in congenital malfor-
mations. Clinical studies have corroborated the finding in ani-
mal experiments that teratogens not only act in their own right 
but may even modify single gene disorders and multifactorial 
diseases. 
Recent large clinical population studies have suggested a 
relationship of alcohol ingestion, diphenylhydantoin, oral con-
traceptives, and even cigarette smoking to the development of 
congenital malformations or repeated spontaneous abortion. 
Two large, prospective studies point out the meticulous care 
that must be used in making a large population study and in 
analyzing the data. In 1974 Milkovich and van den Berg studied 
the teratogenic effects of meprobamate and chlordiazepoxide in 
19,044 live births. They found that when the drugs were taken 
during the frrst 42 days of pregnancy, the rate of severe congen-
ital anomalies (congenital heart disease, mental retardation, 
renal agenesis, etc.) was higher than in a control population 
that did not take these two drugs during that time. In a similar 
study in 1975 with over 50,000 pregnancies, there was no statis-
tical difference in the rate of severe congenital anomalies in the 
drug treated and control groups. The latter study controlled its 
analyses for a wide variety of risk factors already known to 
increase rates of congenital malformations; the former con-
trolled only for anxiety in their treated and control populations. 
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This difference in method probably accounts for the different 
results. 
The interaction of genetic disease and environmental factors 
has already been well described with the X-linked recessive 
disorder, glucose-6-phosphate dehydrogenase deficiency. The 
defect does not become clinically apparent until the patient is 
exposed to an antimalarial drug. More recently, the Wernicke-
Korsakoff syndrome has been shown to be associated with 
recessive inheritance for absence of a specific enzyme. The 
disease becomes apparent only when the factor, thiamine, is 
deficient in the diet, and thiamine deficiency alone does not 
cause the disorder . 
Only 2 population studies specifically on congenital cutaneous 
malformat ions have been made, one of 1,000 newborns in 1976 
the others of 4,600 newborns prospectively (Table II). In th~ 
latter investigation, approximately 7% of all the newborns had 
a cutaneous lesion and in 1.3% the lesions were of potentially 
serious import: premalignant, or congenital nevocellular nevi 
or sebaceous nevi of Jadossohn. A total of 2.6% had cafe-au-lait 
marks. No white infant had more than one cafe-au-Iait at birth. 
This finding might be significant for the early diagnosis of 
neurofibromatosis. Three tenths of a percent of infants were 
born with a hypopigmented tuft of hair. One of these infants 
had tuberous sclerosis at the age of 6 months. This hair fmding 
might be one of the earliest visible markers for the disease and 
does not require Wood's light examination as does the detection 
of hypopigmented macules. Capillary hemangiomata were 
noted in 0.5% of the newborns, however, no follow-up studies 
could be made. Unfortunately, the total sample size of 4,600 
newborns is comparatively small and follow-up studies could 
be done for only one year. 
Needs for Additional Basic Research 
Laboratory research should center on finding chemiCal 
markers of genetic disease and defining environmental terato-
gens. The HL-antigen system serves as an excellent model for 
future evaluation of the gene product. The HLA complex is 
organized upon chromosome number 6. We should look for 
physiological control loci on other chromosomes and, if found, 
determine their incidence in a variety of developmental dis-
eases. The physiological nature of the control locus might serve 
to guide the scientist to those diseases most profitable for study. 
In addition to control loci, chemical markers that are fetus 
specific (similar to alpha-fetoprotein) should be evaluated to 
ascertain whether they are also disease specific. 
Identification of specific chemical markers will allow prenatal 
diagnosis by amniocentesis in pregnant women who have pre-
viously given birth to an affected child. With further research 
and development it should be possible to determine the marker 
in maternal serum, thus avoiding amniocentesis. Serum from 
all pregnant women could then be screened for markers of the 
most common and severe genetic skin diseases. As a fmal step 
the population at large could be 'screened for their genetic 
TABLE II. Congenital cutaneous malformations in a newborn. population of 4641 infants and distribution by race 
M"lformation 
Distribution by race 
Incidence (%) 
Black White Mexican Puerto Rican Oriental 
Nevocellular nevi 1.0 18.8 58.3 8.3 4.2 10.4 
Cafe au Lait spots: 
1 spot 1.9 62.0 9.1 11.4 9.1 3.4 
2 spots 0.5 91.7 0 8.3 0 0 
3 spots 0.2 90.0 0 10.0 0 0 
Zosteriform melanocytic nevi 0.2 85.7 0 14.3 0 0 
Multiple lentigo 2.3 84.2 0.9 ILl 1.9 1.9 
Sebaceous nevi 0.3 lS.4 69.2 IS.4 0 0 
Hemangiomata: 
Cavernous 1.3 5.1 76.3 13.6 1.7 3.3 
Capillary O.S 4.S 86.S 4.S 4.S 0 
Ligh t tuft of ha ir 0.3 6.7 80.0 6.7 0 6.7 
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predisposition control loci. High-risk couples for specific dis-
eases could be defmed, and prenatal diagnosis could then be 
directed toward that specific disease before the birth of an 
affected child. The incidence of birth defects in the general 
population could be greatly reduced by such processes. 
It is not inconceivable that in the future, after finding the 
abnormal gene product of a specific disease, in utero therapy of 
that disease could be undertaken. Enzyme replacement therapy 
is under study now in several genetic diseases that are known 
to lack a specific enzyme. Similar research for dermatologic 
disease deserves considerable support. 
Assays are used now to screen carcinogenic agents. Labora-
tory research on evaluation of environmental teratogens should 
be directed toward the development of similar rapid, simple, 
and accurate in vitro assay systems that would make screening 
of large numbers of substances possible. 
Needs for Additional Clinical Research 
Basic research, to reach its highest productivity, must be 
coupled with sound clinical studies of genetic disease and con-
genital malformations. Populations should be studied prospec-
tively beginning with mothers and fetuses early in pregnancy 
before there is any knowledge of congenital malformation. After 
all the cutaneous lesions in a study of newborns over a defined 
period of time have been diagnosed, follow-up studies should 
begin. Correlations should be made on the incidence of different 
kinds of lesions. Exposure of pregnant mothers and newborn 
infants to environmental teratogens, drugs, diseases, geographic 
influences, racial ancestry, and dietary habits should be defined, 
as they all may have a bearing on the production of congenital 
malformations. Through lengthy and thorough studies the em-
pirical risk factors for all cutaneous lesions present at birth can 
be known and suitable action taken. 
3. NEUROFIBROMATOSIS 
Von Recklinghausen neurofibromatosis (NFT) has long been 
grouped with other disorders, including also tuberous sclerosis 
(TS), Hippel-Lindau disease, and others in the nosologic cate-
gory of "phakaomatosis." This classification is at best anach-
ronistic since it has been used so loosely and implies nothing 
about pathogenesis. If any broad grouping is useful, it is that 
designated by the term "neurocristopathies" because the group 
is then identified according to the embryologic cells that con-
tribute to each of the disorders' primary features. Included in 
neurocristopathies are NFT, TS, and the multiple mucosal 
neuroma syndrome (MMNS) and others. Another useful des-
ignation for essentially the same group of disorders is the 
"APUD concept." "APUD" conveys the idea that the involved 
(neural crest) cells demonstrate "amine precursor uptake and 
decarboxylation" that in turn underly their physiologic func-
tions. 
Rather than discuss each of the myriad disorders that are 
included in the neurocristopathy and APUD designations the 
main focus of this report will be NFT as a prototype for future 
investigative work. 
Prevalence and Severity 
The prevalence ofNFT has been variously estimated to range 
from 1/7800 to 1/3200, although both of these figures probably 
underestimate the birth incidence, since 39-95% of persons with 
the mutant gene apparently escape detection. Thus, NFT is a 
relatively common mendelian disorder. Moreover, each person 
with the NFT gene has a 50% chance of transmitting it to each 
offspring . This fact, plus the high penetrance of the gene and 
its high genetic fitness indicates that in affected families one 
might expect a relatively large number of affected individuals. 
Given the prevalence figures as noted, one might expect 28,000-
68,000 affected individuals in the United States. If 30% of those 
with the NFT gene have more than minimal disease, 8,400-
20,400 NFT patients may be expected to be in need of medical 
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attention. Among those actually brought to medical attention 
the severity ranges from modest cosmetic skin problems, to 
epilepsy, mental retardation, hormonal disturbances, or-
thopedic deformities (e.g., kyphoscoliosis) , central nervous sys-
tem (CNS) tumors and cancer (e.g., neurofibrosarcomas, malig-
nant Schwannomas). Although occasionally the clinical course 
is brief, ending in infancy, it is usually chronic and protracted 
with multiple medical and surgical needs. Thus quality of life 
is frequently affected in varying degrees, usually over prolonged 
periods and at substantial cost. A conservative estimated cost 
for medical care in such chronic, multifaceted diseases is $10,000 
per patient; for the 8,400-20,400 patients noted above the 
cumulative cost would then be from $84 million to $204 million. 
However, other costs less easily estimated must be taken into 
consideration, such as those arising from occupational and 
intellectual handicaps, and from invalidism. Many of the severe 
symptoms, especially seizures, mental retardation, kyphosco-
liosis, and intracranial tumors occur in youngsters, and lead to 
reduced productivity and often to death. It is almost impossible 
to assess the overall financial impact of NFT in wasted lives, 
invalidism, and welfare. 
Prevention, Treatment, and Cure 
Presently, management is mainly symptomatic and palliative, 
aimed at minimizing the adverse impact of further develop-
ments of the disorder. We are powerless to prevent their occur-
rence because we do not yet adequately understand NFT's 
pathogenesis. The only preventative measures available are 
those of genetic counseling to affected individuals. However, 
even this approach is of limited value since about half of new 
cases represent new mutations. The future will hold promise 
only if and when prenatal diagnosis affords an affected person 
the possibility of avoiding affected children without denying 
the possibility of unaffected ones. Prenatal diagnosis involving 
amniocentesis relies on detecting genetic linkage systems 
(whereby a "marker" gene indicates the probable presence of 
the NFT gene) or more direct assays for products of the gene 
or its effects. Developing direct assays, however, will require a 
major research program aimed at finding the basic defect in 
NFT. Very little research has been directed towards this goal. 
Status of Research Activities 
There has been little basic research on NFT. However, basic 
research directed at the differentiation, physiologic and bio-
chemical behavior, histologic and ultrastructural aspects of 
new·al crest and its derivative cells is currently active. Poten-
tially the most informative activities are those that are aimed 
at understanding the mechanisms of migration of cells from the 
neural crest, their differentiation and interaction with other cell 
types, and their potential and final biochemical capabilities. 
Applied, or clinical, NFT research has been purely descriptive 
and lacking in any comprehensive, integrated formulations of 
pathogenesis. Most publications have been population, family 
and case studies aimed at assessing mutation rates, variable 
expression and natural history. 
Neurofibromas, other NFT tumors and cafe-au-lait spots 
have been studied with the electron microscope. NFT tumors 
have also been explanted into cell culture, and they have been 
shown to have a multicellular origin, an important consideration 
in trying to explain tumor origin. Nerve growth factor (NGF), 
a likely suspect in NFT pathogenesis, has been the subject of 
many studies. All of these studies and their resulting data have 
not yet led to a comprehensive, tried, and tested explanation of 
NFT pathogenesis. 
Needs for Additional Basic Research 
Much needs to be learned about how cells migrate from the 
neural crest, how they differentiate, and how they interact with 
other cell types in vivo and in tissue culture. The intracellular 
chemical processes that reflect neural ~rest origin need to be 
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explored with cytochemical and immunocytochemical probes. 
Particular emphasis should be placed on melanin synthesis and 
the processes of amine precursor uptake and decarboxylation. 
Areas of technology worth developing are (1) methods to follow 
neural crest migration and differentiation, (2) new cytochemical 
and immunocytochemical probes of neura l crest-derived cell 
function, (3) probes of melanin synthesis, and (4) methodologies 
to clarify mechanisms of cellular interaction. A larger number 
of investigators need to be encouraged to apply these techniques 
in unified, imaginative ways to discover the intracellular NFT 
defect and how it manifests itself. 
We do not know of a clear-cut counterpart to human neuro-
fibromatosis mutation in other mammals. This is peculiar since 
NFT is one of man's most common dominant mutant disorders. 
A systematic attempt to derive and isolate such a mutation 
would probably be successful. Study of such a system would be 
the best way to clarify the pathogenesis of neurofibromatosis 
and, along with it, define principles relevant to the behavior of 
many autosomal mutations. 
Needs for Additional Clinical Research 
The applied/clinical research needs are of 2 types: prospec-
tive natural history studies with special attention to variants 
and expression, and genetic-linkage studies for chromosomal 
assignment and for genetic counseling and prenatal diagnosis. 
Collaborative investigations will be the key to the understand-
ing of neurofibromatosis. Neurofibromatosis has an embryol-
ogical onset and manifests itself in all phases of life. It involves 
directly or indirectly organs and tissues within the purview of 
every medical discipline. Thus, the need for interdisciplinary 
and interinstitutional collaboration is a major, if not the major, 
requirement in studying neurofibromatosis. 
4. HERITABLE SKIN DISORDERS WITH DNA 
INSTABILITY 
Persons with any of the rare heri table disorders listed in 
Table III exhibi t one or more of the following abnormalities: 
cutaneous photosensitivity, telangiectasia, hyperpigmentation, 
atrophy, hyperkeratosis, disturbances in growth, neurological 
dysfunction, premature senility, and an increased incidence of 
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malignancy. Those with the first 6 disorders in the list share a 
predisposition for "unstable" DNA as shown by the relative 
inability of their cells to repair damaged DNA or by the high 
freque ncy in their cells of spontaneous or induced chromosomal 
aberrations. Although it is generally suspected that the prob-
lems of persons with the last 4 disorders in the list have a 
similar cause, their cells have not yet been shown to have DN A-
repair defects. 
Prevalence and Severity 
None of these conditions is common. The frequency ofxerod_ 
erma pigmentosum, for example, is 1 in 4 million and that for 
ataxia telangiectasia is 25 in 1 million. Most are autosomal 
recessive diseases, however, and it is likely that a much higher 
proportion of the population carries a single copy of the mutant 
gene. One percent of the population, for example, is estimated 
to be heterozygous for ataxia telangiectasia. 
Persons who are afflicted with any of the conditions listed in 
the table experience severe discomfort and inconvenience . Life 
span is shortened in every instance and quality of life is gener-
ally reduced. From early childhood, some live with the threat 
of malignant diseases. Those who develop cancers must undergo 
appropriate therapy. Those with neurologic disease or impaired 
intellect may require institutionalization. The cost to society in 
dollars and in loss of productivity is great. Persons who are 
carriers sometimes exhibit to a partial degree certain features 
of the disorders. Defective genes in carriers may contribute to 
the frequency of cancer , the rate of aging, and susceptibility to 
many environmental stimuli. Their significance in terms of 
medicine and economics is clearly substantial. 
Prevention, Treatment, and Cure 
P revention of these disorders depends upon identification of 
carriers who are at risk and upon making prenatal diagnoses of 
affected individuals. With present methodology it is possible to 
identify carriers of some of these disorders as well as some 
affected persons (e.g., xeroderma pigmentosum, ataxia telan-
giectasia, dyskeratosis congenita, the Bloom syndrome). The 
laboratory tests used are complex, however, and they are not 
widely available. The tests are not appropriate for genetic 
TABLE III 
Disease 
1. Xeroderma Pigmentosum 
(all 5 complementation groups) 
2. Xeroderma P igmentosum Variant 
3. Ataxia te langiectasia 
4. Fanconi's pancytopenia 
5. The Bloom syndrome 
6. Dyskeratosis congenita 
7. Hutchi nson-Gilford progeria 
8. Werner syndrome 
9. Cockayne syndrome 
10. Rothmund -Thomson syndrome 
Inheri tance pattern 
Autosomal 
Recessive 
Autosomal 
Recessive 
Autosomal 
Recessive 
Autosomal 
Recessive 
Autosomal 
Recessive 
X-linked 
Recessive 
Autosomal 
Recessive 
Autosomal 
Recessive 
Autosomal 
Recessive 
Autosomal 
Recessive 
Observations relative to basic defect 
Cellular photosensit ivity; defective excision repa ir of pyrimidine dimers and 
chemical DNA damage. 
Cellular photosensit ivity; defective postreplication repair of pyrimidine dimers. 
Cellular sensitivity to X-rays; some cells defective in postradiation repair repli-
ca tion. 
Cellular sensitivity to DNA crosslinking agents. 
Increased spon taneous chromosomal breaks and sister chromatid exchanges. 
Increased sis ter chromatid exchanges after psoralens plus light; persistent psor-
alen-DNA crosslinks 
Posible accelerated rate of cellular aging 
? 
? 
? 
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screening except with families who are already known to be at 
high risk. Most tests require that cells be grown in culture. The 
procedures are slow and tedious and with knowledge presently 
available there is no possibility of streamlining the tests. 
Treatment requires patients to avoid exposure to the precip-
itating events, such as ultraviolet ligh t, gamma irradiation, or 
chemicals. Patients are never entirely successful in these en-
deavors, and treatment is ultimately directed toward sympto-
matic relief of t he degenerative or neoplastic states that de-
velop. None of the diseases can be cured. 
Status of Basic Research 
In discussing such disastrous experiments of nature as these 
it is difficult to sound hopeful. This should not be the case, 
however, because research progress in t he field in recent years 
has been remarkable and there is now intense scientific interest 
in t he field of DNA repair. 
T he central significance of DNA in normal biologic functions 
is increasingly evident. Genetic information is stored in DNA 
and passes to progeny cells by way of replicated DNA. New 
information is added to the genome by incorporation of new 
DNA through such processes as recombination and transfor-
mation. During differentiation or cellular specialization some 
portions of DNA are permanently inactivated. Certain segments 
of DNA may be temporarily used more extensively during 
transcription. There is clearly strong biologic pressure for main-
tenance of the structural integrity of chromosomes in which 
DNA resides. 
Mammalian cells have developed several mechanisms for 
repairing damage to DNA: excision repair, postreplication re-
pair, and strand-break repair. Excision repair is of 2 sorts. In 
nucleotide excision segments of DNA are removed and replaced 
in a series of enzymic steps by means of endonucleases, exonu-
cleases, polymerases and Jigases that act on a long patch of 
DNA (e.g., UV repair) or on a short patch of DNA (e.g., X-ray 
repair). In base excision an enzyme such as a glycosidase acts 
on damaged bases and does not necessarily break the covalent, 
s u gar-phosphate DNA backbone. Photoreactivation repair is 
an excision system that employs enzymes that are active only 
after exposure to additional light. Postreplication repair takes 
place during or after DNA replication and produces normal 
progeny DNA. Damage to the parental DNA template is re-
paired slowly, if it is repaired at all. Postreplication repair is 
probably more prone to errors t han is excision repair. In strand-
break repair disruptions in the DNA backbone can be sealed 
without removal of DNA. 
The morphologic and numerical characteristics of normal 
chromosomes have been defined. With new ultrastructural 
techniques and cytochemical stains it is possible to identify 
chromosomal bands and with such markers it is easier to 
recognize deletions. It is likely that sister chromatid exchanges 
are cytogenetic evidence for chromosomal breaking and rejoin-
ing. 
Abnormalities in any of these factors may indicate instability 
of t h e genetic material. Table III contains a list of the obser-
vations that show there is DNA instability in each of the 
conditions under study. 
Status of Clinical R esearch 
Xeroderma pigmentosum (XP) was the first disorder for 
which a DNA repair defect was found . Persons with XP are 
extremely sensitive to ultraviolet light in the sunburn spectrum. 
They develop abnormal pigmentation and some have ocular 
and neurologic disease. Cutaneous malignancies appear in child-
hood, and patients ultimately die from consequences of their 
skin tumors. Cells from patients with XP are defective in 
excision of UV -mediated pyrimidine dimers in DNA as well as 
in excision of chemical damage to DNA. Defective excision 
repair is caused by a relative absence of UV endonucleolytic 
activity in XP cells. The same defect is responsible for abnormal 
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response of XP cells to certain viral infections. T he UV sensi-
t ivity of XP cells can be partially corrected by adding purified 
viral UV endonuclease. T he 5 complementation groups of XP 
cells differ in their degree of UV sensitivity and in t heir relative 
rates of dimer excision. The XP variant cells are defective in 
postreplication repair. There are slight clinical differences 
among patients whose cells are in different complementation 
groups; however, all XP patients present a similar phenotype. 
Ataxia Telangiectasia (AT) is characterized by progressive 
neurological degeneration that leads to incapacitative cerebellar 
ataxia. Persons with AT develop telangiectatic lesions on skin 
that is exposed to sun and to friction; however, they do not 
have photosensit ivity. Patients are subject to lymphoprolifera-
tive neoplasms and die at an early age from their malignancies. 
Cells from persons with AT are abnormally sensitive to gamma 
radiation and show abnormal repair replication after exposure 
to X-rays. Clu-omosomes of patients with AT show numerous 
spontaneous breaks and gaps which are especially marked after 
exposure to X-rays. 
The Bloom Syndrome is characterized by short stature and 
telangiectatic lesions on sun exposed skin . Patients have a 
predisposition to lymphoproliferative malignancies and other 
neoplasms to which they ul t imately succumb. Chromosomes of 
cells of these persons show numerous breaks, rings, and other 
abnormal forms. The spontaneous rate of sister chromatid 
exchanges is greatly increased. 
Dysheratosis Congenita (DKC) is characterized by cuta-
neous telangiectasia, reticulated pattern of hyperpigmentation, 
progressive loss of nails, a predisposition to mucocutaneous 
malignancy and pancytopenia. Chromosomes of cells of patients 
with DKC show a greater increase in sister chromatid exchanges 
after exposure to psoralens plus UV ligh t t han do cells of normal 
persons. Cells of patients with DKC show delayed excision of 
psoralen-DNA cross-linking photoadducts. 
In addition to their hematologic abnormalities, persons with 
the Fanconi Pancytopenia have multisystem abnormalities, 
including defects in the skeleton, heart, and kidneys. These 
persons also have cutaneous hyperpigmentation and an in-
creased frequency of malignancy. Cells are more susceptible to 
DNA cross-links produced by mitomycin C and there are in-
creased chromosomal aberrations of several kinds. 
Needs for Additional Basic Research 
It is first necessary to identify defective gene products. Prog-
ress depends upon improved and simplified culture techniques 
for cutaneous and fetal c~lls and upon developing new microen-
zymological probes. 
These diseases reflect the stability and integrity of DNA. 
Therefore, studies should be supported to find all the ways in 
which DNA can be damaged. We must also learn what defenses 
the cells have against DNA damage. How to correct t he damage 
once it occurs is predicated on knowledge of the process of 
DNA repair; specifically, we need to know much more about 
t he rates at which various repair processes can operate and 
whether or not repair is accurate. 
Progress in this area also depends upon progress in 3 other 
~cientific disciplines: radiobiology, DNA repair, and cytogenet-
ICS. 
Needs for Additional Clinical Research 
Although research into better treatment of these ral'e DNA 
disorders is certainly desirable, studies to improve prenatal 
diagnosis and to identify carriers may be more generally re-
warding. As more simple assays become available to identify 
heterozygotes, t hey should be put to use in large scale screening 
procedures. Test results should t hen be correlated with other 
health information on t he persons screened. 
Genes responsible for these disorders seem to exert some 
control over normal growth, maturation, and development and 
must partly determine the susceptibili ty to infection and malig-
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nancy. Studies should be undertaken to determine whether 
heterozygotes may be at a much greater risk than normal 
people to various environmental and pharmacological agents. 
Diseases associated with unstable DNA are extremely rare 
and no one center can hope to see very many affected persons. 
Therefore, interinstitutional cooperation must be encouraged. 
Cell culture banks, such as the Institute for Medical Research 
and the American Type Culture Collection need support. Close 
cooperation is required among dermatologists, geneticists, ra-
diation biologists, and many other disciplines. 
5. ICHTHYOSIS AND CONGENITAL DISORDERS OF 
KERATINIZATION 
Ichthyosis and congenital diseases of keratinization affect 
approximately l.0% of the population; in 10% of those affected, 
it is of great concern. The diseases within this class are ich-
thyosis vulgaris, X-linked ichthyosis, lamellar ichthyosis, epi-
dermolytic hyperkeratosis, pityriasis rubra pilaris and Darier's 
disease. 
Prevention, Treatment, Cure 
There is no specific treatment for this group of diseases. 
Many patients are benefitted by change to an environment that 
is warm and moist. Patients with the most severe forms of these 
diseases often have difficulty in getting a satisfactory education 
and a satisfactory livelihood. Many of the patients with the 
severe forms of these diseases are unable to earn a livelihood 
and must rely upon welfare. As with other genetic diseases 
experience suggests that there is a discrete molecular defect 
peculiar to each of these disease states; only knowledge of the 
specific molecular flaw will produce specific cures. 
Status of Research 
There have been a variety of biophysical and biochemical 
studies performed on the skin and on the general body metab-
olism of patients with ichthyosis. Biophysical studies have 
suggested that, in some forms of ichthyosis, an abnormal struc-
tural protein is made in the epidermis; in other forms of ich-
thyosis, both microscopic and biophysical studies have sug-
gested that maturation of the epidermis is incomplete. Bio-
chemical studies not only confirm these biophysical findings; 
they also show multiple variations in the epidermal proteins. 
Studies in which the epidermis have been grafted to nude mice 
have demonstrated that the biochemical defect in at least some 
forms of ichthyosis is limited to the epidermis itself. The defect 
is not correctable by a cograft with normal human dermis or by 
the various diffusible factors present in the nude mouse. Bio-
chemical studies have shown discrete metabolic defects in lipid 
metabolism associated with ichthyosis (e.g., Refsum's syn-
drome, neutral lipid storage disease, steroid sulfatase defect) 
and abnormalities of lysosomal enzyme metabolism (mannosi-
dase deficiency). 
It is to be noted that a phenocopy of ichthyosis vulgaris 
OCCUJ'S in Hodgkin's disease. Many patients. with this disease 
develop a thin granular layer and scaling skin. Upon treatment 
of Hodgkin's disease, the epidermis returns to normal. The 
molecular basis of the secondary ichthyosis in Hodgkin's disease 
and other neoplastic disorders has never been clarified. In-
creased epidermal kinetics accompanies some forms of ich-
thyosis. 
Topical agents are used to treat ichthyosis. Many of these 
agents, such as glycerin, have been used for decades; new 
agents, such as hydroxyacids, vitamin A acid, a nd propylene 
glycol, that are suitable for some forms of ichthyosis have 
recently been developed. Systemic vitamin A analogues are also 
useful in treating some forms of ichthyosis. 
There are approximately 5 research groups in this country 
equipped to study the chemistry of keratinization and fewer to 
study the biophysics and biochemistry of the abnormal dermis. 
Studies of this disease require clinical facilities, clinical research 
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units, and possibly environmental chambers. The laboratory 
technology in use at the present time includes electrophoretic, 
chromatographic, and amino acid analysis of skin samples from 
patients with concomitant studies of their organic acid metab-
olism. Envu'onmental conditioning chambers suitable for long-
term home use have not yet been developed. 
Needs for Additional Basic Research 
To understand the molecular basis of the several forms of 
ichthyosis we need to better understand the relationship of the 
structure of the epidermis to its biochemistry. Basic studies are 
needed on epidermal synthesis of protein, lipid, and carbohy-
drate in relation to ultrastructure in ichthyotic skin. 
We need to fmd out whether the epidermal defect in ich-
thyosis can be corrected in co-culture experiments with normal 
and abnormal epidermis. This should be feasible with present 
culture methods; however, standardization and training are 
necessru·y. Standardized epidermal tissue culture facilities 
should be developed and training workshops should be held to 
increase the number of workers in this area. 
Kinetic studies are needed to determine whether these dis-
orders of keratinization are hyperproliferative and, if so, 
whether the whole epidermis is involved or whether new cell 
compartments are recruited into proliferation. Systematic elec-
tronmicroscopic studies of biopsies from all patients with ich-
thyosis should be made. Careful studies of the cell surfaces in 
both affected skin in culture and in the nude mouse model are 
essential. 
Needs for Additional Clinical Research 
New topical therapies need to be developed for these diseases. 
Emphasis should be placed on compounds that will at the same 
time control epidermal proliferation and hydrate the stratum 
corneum. Systemic therapy in which vitamin A analogs and 
antimetabolites are used should be given adequate study. 
Patients with ichthyosis arising from Hodgkin's disease and 
other malignancies should be studied to see if the overproduc-
tion or underproduction of a specific metabolite might be re-
sponsible for the secondary skin condition. 
Finally, increased effort should be placed on developing 
methods for prenatal detection of ichthyosis, especially for the 
severe forms. 
6. HAIR DISORDERS 
Hair disorders cause much grief and anguish but little mor-
bidity or mortality. Government supported hair research has 
been at a very low level. A rational approach can be taken to 
the study of genetically caused defects in hair. Since the hair 
defects are often manifestations of a more generalized problem, 
new knowledge within this group of disorders is of general 
interest. 
Prevention, Treatment, Cure 
The only specific treatments for th.e diseases to be discussed 
or for the more common hair di&eases, such as hormonally 
determined alopecia and alopecia areata, are cosmetic. These 
are not very effective. Experience with other genetic diseases 
suggests that once specific molecular defects can be identified 
more specific treatments can be developed. 
Status of Research 
The genetically determined disorders of hair can be used as 
probes of the functioning and organization of the hair follicle 
and the fully .keratinized hair. A large number of different 
genetic diseases are expressed as alterations in structure or 
composition of hair. These diseases deserve comprehensive 
analysis, since their study and the complete elucidation of their 
molecular pathology will aid our understanding of the biology 
of hair. 
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Since the hair is almost completely protein, studies of its 
structure have emphasized the hair's structural proteins. Ab-
normalities in the primary structure of hair protein have been 
found; ornithine transcarbamylase deficiency, (nucleic acid pre-
cursor imbalance is associated with abnormal hair); kwashior-
kor (limitation of protein or protein malnutrition produces 
abnormal hairs); argininosuccinicaciduria (abnormalities of the 
urea cycle are associated with defective hair). These are disor-
ders associated with deficiency of several of the subclasses of 
.hair proteins: deficiency of the high-tyrosine proteins, defi-
ciency of the high-sulfur proteins. There are also abnormalities 
of cross-linking of the hair proteins: hidrotic ectodermal dyspla-
sia, Menke's disease, cartilage-hair hypoplasia. 
These basic abnormalities in hair can lead to disorders of 
organization and orientation of hair, changes in the cyclic 
activity of hair follicles, and possibly partial or complete sup-
pression of follicle initiation of hair synthesis. 
The macromolecular structure of hair (or wool) is immensely 
complicated. It can be studied with a variety of techniques. The 
intact fiber can be studied mechanically by X-ray diffraction 
~nd by optical and electron microscopy. The features revealed 
by these have served as the basis for models of wool structure. 
In detailed structural studies of hair, it is necessary to separate 
the fiber into its anatomical parts so that the intrinsic hair 
proteins can be dissolved. Most studies of normal and abnormal 
hair are done on intact hair or intact hair roots. Therefore, most 
preparations of extracted proteins are immediately heteroge-
nous on this basis alone. 
In the cortex and cuticle there are many proteins rich in 
cystine. The cystine is involved in intramolecular and inter-
moleculru' disulfide bonds. These proteins are solubilized by 
disulfide bond reduction and subsequent isolation. Recent stud-
ies have demonstrated a second post-translational crosslinking 
system in addition to disulfide bands in hair. This system forms 
very stable e-(y-glutamyl) lysine bonds and stabilizes hair, es-
pecially the medulla and internal root sheath. 
Needs for Additional Basic Research 
We need to know how hair proteins are synthesized and how 
they are modified after synthesis. Also, since there has been 
scant attention to structural lipids and carbohydrates in hair, 
these are in need of investigation. Clinical observations of 
hirsutism in mucopolysaccharide storage disease; substantiated 
by laboratory experiments, suggest that mucopolysaccharides 
may be involved in controlling hair growth. Such involvement 
should be more systematically explored. 
The cycling mechanism in hair deserves careful investigation. 
A genetic study of people with abnormally long or abnormally 
short hair might clarify this mechanism. The study of the 
increased lanugo hair in malignancy might lead to the identifi-
cation of other factors that control hair growth. 
Development of a tissue culture system so that hair growth 
may be defined under in vitro conditions is fundamental to the 
advancement of knowledge, and sensitive nonradioactive quan-
titative techniques to determine kinetics of human hair are also 
greatly needed. 
Needs for Additional Clinical Research 
By identifying specific defects, discrete treatment of hair 
disease will be possible. Treatment advances will depend on 
acquiring such basic knowledge as outlined above. Collabora-
tion of dermatologists with pediatricians and experts in genetic 
disease is necessary to make a complete study of patients with 
mucopolysaccharide and other metabolic disorders, with oncol-
ogists to ascertain the molecular basis of hypertrichosis lanu-
ginosa, and with nutritionists to study the effects of protein and 
protein-calorie malnutrition on hair. As many of these diseases 
are infrequent, interinstitutional cooperation and reference lab-
oratories for specific biochemical and biophysical tests will be 
necessary. International cooperation would be helpful in study-
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ing the effects of extreme protein and calorie malnutrition on 
hai.r. 
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APPENDIX: 
ANIMAL MODELS OF HERITABLE DISEASES OF SKIN 
Animal models are a valuable resource for studies of heritable 
diseases affecting skin. At the present time, this resource includes 
models for diseases affecting epidermal, adnexal, and connective tissue 
elements of skin, models for disorders of pigmentation, vascularity and 
lymphatics models for immune mediated cutaneous injury, and models 
for systemic metabolic disorders with cutaneous manifestations (See 
Table). Studies of only a few of these models have been extensive, yet 
these have invariably led to notable advances in our understanding of 
the d isease process in both man and animals. Many potential models 
have been forgotten over the years or poorly developed. Progress with 
those that have been studied has been much slower and more difficult 
than necessary. In many cases the dissemination of information about 
new models has been slow, and in some cases the dissemination of 
Vol. 73, No. 5, Part II 
specimens or breeding stock to other laboratories has never occurred 
or has been quite limited. If the problems that cause delays in the 
development of new models can be identified and circumvented a 
much larger proportion of the biomedical research community will 'be 
able to benefit from the many advantages of an imal models for studies 
of the pathogenesis, prevention, and treatment of both heritable and 
acquired diseases of skin. 
Advantages of Studying Animal Models 
A brief consideration of some of the advantages of animal models 
should help to emphasize th", fact that the biomedical research com-
munity can benefit greatly, both from an increased awareness of the 
importance of these resources and from their increased utilization. For 
example, most sCientists are aware of the advantages of inbred strains 
of laboratory rodents formany types of genetic. analyses, including the 
mapping of gene mutatIOns and other genetic studies requiring an 
inbred background or large numbers of progeny. Many, however are 
not aware of the advantages of naturally occurring heritable disea~e in 
domestic animals for basic studies of the etiology, pathogenesis treat-
ment, and prevention of diseases affecting man. ' 
. Patterson has. recently gro.uped the advantages of animal studies 
Into: (1) availability, (2) genetic diverSity and population structure (3) 
ascerta inment (identification), (4) clinical delineation (characte;iza-
tion), and (5) suitability for studies of the pathophysiology of the 
disease process. 
Availability. Millions of dogs, cats, horses, cows, sheep, goats and 
swine a re bred and maintained in this country, and they are const~ntly 
producing offspnng with Inhented disorders. These animals provide 
large populations for study by the medical geneticist. In dogs alone 58 
genetic diseases have been identified to date, and 6 of these are either 
homologs or analogs of specific diseases of the skin of man. These 
include atopic dermatitis, a dominant collagen packing defect (Ehler-
Danlos syndrome), ha irlessness, and an ectodermal dysplasia. In addi-
tion to this are the other disease models shown in the Table that have 
been iden,tified in cats,. c0:-vs, horses, sheep, swine, and laboratory 
rodents. 1 he ready ava tIabLhty of these natural disease models is an 
advantage of this resource. 
Diversity. Inter- and intra-species genetic diversity of domestic ani-
mals is advantageous to research efforts. Specific breeds within each 
species represent genetically isolated, yet heterogeneous populations. 
Heritable defects of shin with analogs in animals and man 
Mode of illhe ril-Primary defect 
Epidermal Defects 
Ectodermal dysplasia 
Epitheliogenesis imperfecta 
Ichthyosis 
Adnexal Defects 
Follicular dysplasia or aplasia 
Hypertrichosis 
Hypotrichoses 
Sebaceous gland aplasia 
Symmetrical a lopecia 
Disorders of pigmentation 
Alb inism or hypomelanogenesis 
Albin ism with deafness 
Melanoma, blue mole, nevus 
Waardenburg syndrome 
Connective t issue defects 
Dominant collagen packing defect I 
(Ehlers-Danlos, type I 
Cutaneous asthenia 
Dominant dermatosporaxis 
Dominant dermatorrhexis) 
Procollagen peptidase deficiency I 
(Ehlers-Danlos type VII, 
Recessive dermatosparaxis, 
Collagenous tissue dysplasia) 
X-linked collagen crosslinking defect 
Cutaneous lymphatic or vascular defects 
Congenita l heredita ry lymphedema 
Immune mediated cutaneous disorders 
Atopic dermatitis 
Systemic metabolic disorders with cutaneous manifesta-
t ions 
Acrodermatitis ente ropa thica 
Menkes kinky ha ir syndrome 
M ucoIJolysaccharidosis 
Species affected 
Pig, dog, man 
Horse, cow, pig, man 
Cow, dog, mouse, man 
Sheep, dog, mouse, man 
Horse, cow, man 
Cow, sheep, goat, mouse, man 
Mouse, man 
Cow, man 
All species 
Dog, cat, man 
Horse, pig, man 
Cat, dog, man 
Cat, dog, mink, man 
Cattle, sheep, man 
Mice, man 
Cattle, dog, man 
Dog, man 
Mouse, man 
Mouse, man 
Cat, man 
ance 
? 
R 
R 
? 
? 
R 
? 
R 
R 
R 
? 
o 
o 
R 
XR 
0 
R 
R 
XR 
R 
References 
1,7,10,34,49,61,63 
4,10,34,36,49,50,58,63 
10, 34, 35, 63, 64, 66, 68 
7, 10, 34,62,63 
10,34,63 
14,15,19, 30,31,32,34, 39, 4 ~, 
55, 56, 62, 63, 69 
21 
29,34,63 
34,63 
3,34,63 
29, 34, 42, 43, 63 
17 
11,24-27,34,52,67 
1,18,22,28,34,37,38,40,48 
13,57,67 
16,20,34,41,45,51, 63 
34, 46, 49, 50, 59, 63 
53 
13, 57, 67 
12, 33, 47 
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Presuma bly, each breed carries a load of recessive mutations that are 
expr essed because of sufficient inbreeding. The effects of genetic iso-
latio n, genetic drift, and inbreeding are readily evidenced by the ap-
pearance of in terbreed di fferences in the incidence of many specific 
heritable defects in animals, just as nationality or racial diffe rences 
affect t he incidence of many diseases of ma n. 
Ascertainment. Even with polygenic sets there is a n increase in the 
incidence of specific defects over that in completely outbred popula-
t io n s. As in ma n, t his may be the frrst clue that a n uncommon disease 
has a genetic basis. Unlike t he situation with man, however, selective 
experimental breeding can be used to extensive ly test an hypothesis 
abou t the role of genetics in the determina tion and expression of each 
d isease process. T his testing may involve studies of the effects of both 
additional inbreeding and outbreeding. Domestic a nima ls, unlike most 
laboratory rodents are not highly inbred. Consequently, domestic ani-
mal models often offer unique opportunit ies to study the effects of 
genetic variation on the expression of a heritable disease. 
C linical delineation. Individual animals often undergo as thorough 
a c linicopa thologic examination as ma n. Therefore, subtle clinical 
ch a n ges are as easily ident ified in domestic anima ls as they are in ma n. 
By combining t his wit h breeding a nd producing larger numbers of 
affected individua ls with a full range of lesions or degrees of clinical 
dysfunction (i .e., variations in the expression of the defect) t he full 
spectrum of primary and secondary e ffects of each heritable defect can 
be c h aracterized both clinically a nd experimentally in domestic a nima ls. 
By selective breeding the defects in heterozygotes can be compared to 
t h e d e fects in homozygotes, a nd the effects of different environmenta l 
influe nces on the expression of the genetic defect can be a na lyzed . Wit h 
affected domestic a nima ls adequate qua ntit ies of tissues or fluids are 
also usually available for essent ially any type of microscopic or bio-
chemical a na lyses. Wit h defects t hat are expressed as congeni tal mal-
for mations, whole fetuses or feta l t issues, ceLIs or fluids may be obtained 
at a n y t ime dur ing gestation. S imilarly, t issues from affected and 
unaffected siblings may be compared directly in every case. 
Pathophysiology. Perha ps most significantly, pa thogenesis of the 
natu ra l d isease process can be dissected experimentally in well con-
tro lle d basic studies. The disease process can be studied in detail in the 
whole organism as well as in cells or t issue from a ffected a nd unaffected 
siblings or from related and unt reated individuals. All available physi-
cal, c hemical, and morphological techniques can be brough t to bear on 
the p roblem, a nd specimens can be distributed to ma ny la boratories so 
that t he best ava ila ble basic expert ise may be brought to bear on t he 
problem. Furthermore, once the pathogenesis of each process is under-
stood, the indicated range of t herapeu tic regimens can be tested in the 
domestic anima l model. The resul ts of all of these basic studies should 
then permi t the physicia n to select the appropriate tests to identify the 
basic heritable defect, to choose t he appropriate environmental or 
therapeutic regimen, and to provide solid predictions on the patterns 
of inheri tance, prevention, remission , circumvention or cure of those 
heritable diseases of t he skin of man that have homologous a nimal 
models. 
Status of R esearch on A nimal Models 
Even though there are many poten tial models of heri table diseases 
of t h e skin of ma n, few models have been exploited. One or two models 
that h ave been studied, however, should ser ve as examples of how our 
understanding of the basic disease mecha msms may often be better 
extended by use of a model tha n by studies of a ffected human patien ts. 
The E hlers-Danlos syndrome in ma n is a group o ~ heritable di~eases 
in w hich various connective t issues are hyperextenslble a nd fragile. In 
man, at least 3 forms' of this syndrome are. inherite~ as a utosomal 
dominant traits, 3 have a n autosomal recessive mhen tance a nd one 
form is an X- linked recessive [67]. T o date, models of one of the 
dominant forms [24,25,52], a nd one of the re~essive forms of this 
syndrome [1 ,18,22,28,38,48] have been identifie.d m ammals. 
S h eep with "del'lnatosp31'a xis" were fU'st dIscovered m Nor~ay in 
1962. S kin from affected lambs was reportedly stored frozen, m t he 
hope t hat someone would study t he defect in the la boratory whe~e it 
was first recognized. This cond ition in sheep was a pparently recogmzed 
as a potential disease model. However, the affected skms were not 
studied for approximately 10 years [18,28,54]: In the m eantime, "der-
matosparaxis" was discovered in calves m BelgIUm a nd Texas 
[1,22,38,48]' In both cases, skin fr om affected calves was promptly 
studied a nd the defect was shown to be due to a defiCiency of procol-
lagen pep tidase [37,~8]. T his d iscover.y i.n cattle quickly led to t he 
discovery of procollagen and revolu tlOl1lzed .our knowledge. of t he 
synthesis, secretion, deposit ion , and organizatIOn of collagen m both 
man a nd a nima ls [67]. In 1973, the skins of t he sheep were fi nally 
studied [18,28,54]' By this t ime t he disease process had a lready been 
rath er thoroughly characterized in cattle, a nd a simil31' defect had been 
found in cultured fibroblasts from huma n patients wit h the E hlers-
Danlos syndrome type VII [40]. 
A delay may also have occurred in t he development of a n a nima l 
model of the E hlers-Danlos syndrome, type I. Dogs a nd mink wi th a 
dominant inheritance of hyperextensible fragile skin were first de-
scribed in 1966 [24]. D ur ing the next 12 years t he histology and cha nges 
in tensile strength of the skin of these animals were described [25,27]' 
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T he biochemical basis of t he disease was not determined, however, and 
t he model was not disseminated to other laboratories for basic studies 
of the pathogenesis of the defect. Recen t studies have shown t hat the 
acid extrac tab il ity of dermal collagen a nd the rate of collagen synthesis 
are both noticeably increased in explants of skin of affected mink [11]. 
A natura l model of the E hlers-Danlos syndrome type I was also 
recently desc ribed in cats [52]. T he skin of these cats was both hyper-
extensible and fragile and the defect was transmitted as a simple 
a utosomal dominant t ra it. E lectron microscopy showed that a defect in 
t he packing of dermal collagen into fibrils and fibers was responsible 
for the a bnormal physical proper ties of the skin of heterozygous cats 
and ki ttens. When 2 affected cats were bred, about one fourth of t he 
embryos died during t he period of organogenesis, suggesting that t he 
homozygous state of t his defect is letha l. At midgestation, presumptive 
heterozygous fetuses had both fragile skin and the collagen packing 
defect. S imilar defects in t he packing of collagen have recently been 
de monstrated in the skin of affected dogs [44] and man [65]. In affected 
and unaffected sibling cats, however, there was no diffe rence in either 
the extractabili ty rates of synt hesis or rates of turnover of dermal 
collagen [44]. The basis of t hese differences between the biochemical 
linding in the affected mink a nd cat skin is not known. Nonetheless, 
t hese models should all prove to be valuable tools fo r studies of 
dominant defects in cutaneous connective t issue. It is hoped that 
curren t studies of the synthesis, deposit ion, a nd turnover of dermal 
connective t issue prote ins in all fou r species will identify t he basic 
biochemical defect in t hese disease processes. It appears likely that this 
knowledge will not only increase our understanding of the Ehler-Danlos 
syndrome type I but will a lso permi t us to a nswer basic questions a bout 
(I) the genetics and regulation of t he packing of collagen in to fibrils 
a nd libe l'S, and (2) the effects of differences in the organization of 
dermal collagen on the physical properties of skin. 
Acroderma.titis en.teropathica in man is an autosomal recessive t rait 
that is exp ressed as a dietary zinc deficiency in some infants when they 
a re weaned fTo m human milk to bovine milk. A similar defect was 
recently found in mice homozygous for the recessive lethal milk muta-
tion. Mice pups nursed on homozygous dams showed stun ting, acute 
dermatit is, a lopecia, a nd death, a nd t hese defects were reduced by the 
administration of zinc [53]. Even though t he plasma zinc levels were 
norma l the content of zinc in homozygous dams' milk was 34% less than 
that in normal dams, suggesting that there was a defect in the transport 
of zinc from plasma to milk in the homozygous dams. T hus, the resul ts 
of studies of t his mouse model may increase our unde rstanding of both 
the mechanisms of Zn transport a nd the basic defect in acrodermatit is 
enteropathica. 
Atopic hypersensitivity in man is a group of allergies including 
asthma, hay fever, eczema, urticaria, allergic rhinit is, serous otitis 
media, atopic conjunctivit is, a nd food a llergies. In both man and the 
dog atopic hypersensit ivity is a complex heritable t rait in which there 
is a n abnormal IgE response to contact allergens [59]. Wit.h t he abnor-
ma l IgE response t here is a localized release of histamine at the site of 
contact. Hence, t he wide ra nge of clinical forms of th is process. S ince 
t his cond it ion has such a t remendous morbidity in man, a spontaneous 
homologous heritable disease in the dog should provide a high ly useful 
too l for basic studies of the inheritance, pathogenesis, a nd preven tion 
of t his disease complex. 
Disorders of pigmentation ranging fro m vitil igo, to nevi, to malignant 
me la nomas in ma n have an el):tremely high morbidity and a significant 
mortality. T he inheritance of these disorders is not clear-cut in either 
ma n or a nimals . Selective breeding in both gray horses [34,42,63] and 
Sinclair swine [43], however, has resu lted in a marked increase in the 
inc idence of pigment cell disorde rs . In S inclair swine pigmented nevi 
progress t hrough t he same stages of growth , regression, and occasional 
maligna nt t ransformation as the mela nocytic nevus in man [29]. T hese 
models should therefore be prime mat.erial for research into the etiol-
ogy, pathogenesis, and cont rol of melanocyte growth in both man and 
a nimals. 
Furthering lhe Use of Animal Models in Dermatology Research 
Domestic a nima l models have not been developed to even a fraction 
of their potentia l in dermatology research. T he fo llowing is needed to 
develop t hese resou rces. 
a. An active prospective program must be created to identify and 
characterize new a nimal models. 
b. Ways must be found to provide adequate support a nd shorten the 
process of developing new models. 
c. A system must be promoted for p romptly disseminating informa-
tion, specimens, and breeding animals to laboratories that will carry 
out the etiological, pathogenetic, a nd disease-control studies. 
d. Means must be provided for cont inued support to clinical inves-
tigato rs a nd basic sc ientists who wor k together to develop usefu l an imal 
models. 
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